Decoy Therapeutics Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Decoy Therapeutics Inc. on May 19, 2026. The filing addresses corporate governance matters regarding the scheduling of the company's 2026 Annual Meeting of Stockholders.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on administrative and procedural updates regarding shareholder meetings.
Material Changes
The Board of Directors established July 14, 2026, as the date for the 2026 Annual Meeting. This date represents a change of more than 30 days from the anniversary of the previous annual meeting, triggering the requirement for this disclosure under Rule 14a-5(f) of the Exchange Act.
Guidance, Outlook, and Corporate Actions
- Meeting Date: July 14, 2026.
- Record Date: Stockholders of record as of the close of business on May 22, 2026, are entitled to vote.
- Proposal Deadlines:
- Rule 14a-8 Proposals: Must be received by the Company Secretary by the close of business on May 29, 2026.
- Advance Notice Proposals/Director Nominations: Must be delivered to the Company Secretary by the close of business on May 29, 2026.
- Universal Proxy Solicitations: Notice required by May 29, 2026.
- Future Filings: Time, location, and other details will be included in the proxy statement to be filed with the SEC prior to the meeting.
Investor Verification Checklist
- Verify the exact time and physical/virtual location of the Annual Meeting once the proxy statement is filed.
- Confirm stock ownership status as of the May 22, 2026, record date to ensure voting eligibility.
- Review the company's Amended and Restated Bylaws for specific formatting and content requirements for shareholder proposals.
- Monitor the deadline of May 29, 2026, for any intended shareholder proposals or director nominations.